Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months
Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months
复制标题
DOI：
10.1136/bjophthalmol-2018-312944
复制
发表时间：
2019-09-01
影响因子：
4.1
通讯作者：
Gillies, Mark C.
中科院分区：
文献类型：
--
作者：
Invernizzi, Alessandro;Teo, Kelvin;Gillies, Mark C.
目的比较抗血管内皮细胞生长因子(抗血管内皮生长因子)治疗的视网膜血管瘤性增生症(RAP)眼与现实世界中诊断为其他新生血管性老年性黄斑变性(NAMD)亚型的对照组的24个月结果。方法治疗-2006年1月至2015年11月期间开始抗血管内皮生长因子治疗的幼稚NAMD眼从NAMD治疗结果登记中鉴定出来。2例为诊断为RAP的眼。在非RAP病变的NAMD患者中，每例选择3例作为对照，在基线视力、治疗开始时间、首次注射抗血管内皮生长因子药物和随访方面进行匹配。比较基线视力与12个月和24个月的视力。比较RAP和对照组的VA变化、接受注射的次数、NAMD活动的就诊比例和第一次失活的时间。结果入选RAP组157例，对照组469例。基线VA(平均值(SD))在12个月时增加(61.4(15.5)个字母对68.7(14.7)个字母，p
Aims To compare 24 months outcomes of eyes with retinal angiomatous proliferations (RAPs) treated with antivascular endothelial growth factor (anti-VEGF) with a group of controls diagnosed with other neovascular age-related macular degeneration (nAMD) subtypes in a real-world setting. Methods Treatment-naive nAMD eyes that commenced anti-VEGF between January 2006 and November 2015 were identified from a registry of nAMD treatment outcomes. Cases were defined as eyes diagnosed with RAP. Three controls per case were selected among nAMD eyes with non-RAP lesions and matched on baseline visual acuity (VA), year of treatment initiation, anti-VEGF agent first injected and follow-up. Baseline VA was compared with 12 and 24 months VA. Change in VA, number of injections received, proportion of visits with active nAMD and time to first inactivation were compared between RAPs and controls. Results 157 RAPs and 469 controls were included. Baseline VA (mean (SD)) increased at 12 months (61.4 (15.5) vs 68.7 (14.7) letters, p